Explore This Research Award in CaptureIQ
Research the technology, evaluate the recipient and agency, identify related opportunities, and explore potential follow-on work with CaptureIQ.
Award details
- Awarding agency
- Department of Health and Human Services
- Branch
- National Institutes of Health
- Recipient company
- CFD Research Corporation
- Proposal award date
- 2020-05-18
- Contract end date
- 2021-04-30
- UEI
- V3KCP1HNFM33
- Solicitation number
- PAR17-199
- Topic code
- NICHD
Research abstract
A mechanism-based computational toolkit to optimize age-specific pediatric pulmonary drug delivery
Project Summary/Abstract:
The selection of the most age-appropriate combination of drug, device, and interface is critical for the effective
administration of any prescribed therapy. This is especially relevant in pediatric cases of respiratory disorders
that require inhalation therapy. However, in spite of all the modern advancements in inhalation therapies, the
fraction of drugs reaching the lungs for maximal therapeutic effects remains low while increasing the dose causes
an increase in systemic concentration and subsequent toxicity. The lack of approved age-appropriate
drug/device combinations has been limited by experimental constraints in children and the plasticity of pediatric
airway structures that continuously evolves from birth to adulthood, influencing airflow dynamics and respiratory
mechanics. Motivated by such shortcomings, which cannot be solved by experimental strategies alone, we
propose to develop a novel multiscale computational toolkit to simulate deposition, dissolution, absorption,
transport, clearance, and actions of inhaled drug products. The core of this toolkit will be an integral framework
of computational fluid dynamics (CFD) and whole-body physiology-based pharmacokinetic (PBPK) models,
specific to selected age groups.
In Phase I, we will (1) develop image-based and anatomically-faithful 3D CFD models of pediatric airway
geometry to calculate age-, drug-, and device-specific deposition patterns; (2) extend the CFD models to account
for various physiological and pathological settings, such as constriction of airway geometry; and (3) integrate
CFD deposition models with PBPK models to estimate systemic concentration of the inhaled drugs. This
workflow, in collaboration with Department of Pediatrics, Pulmonology Division at the University of Arkansas
College of Medicine, and Department of Radiology at Duke University, will primarily focus on modeling two test
subjects for corticosteroid inhalation using two commonly used pediatric inhalation devices. In Phase II, we will
further improve our computational tools by model validation on additional pediatric age-groups, drugs and drug
combinations, and other pediatric inhalation devices, such as, nebulizers and soft mist inhalers. Our goal of using
these computational strategies is to develop a product that will aim to facilitate drug development by identifying
key biopharmaceutical factors affecting efficacy and safety of inhaled drugs that help guide age-appropriate
dosing, device, and interface selection to better inform clinical practice.
The final deliverable will be a commercial quality software package with graphical and instant response abilities
to estimate regional and global deposition of inhaled drugs in the human respiratory tract and their fate through
its appearance in the systemic blood until eliminated from the body. The software with pre-loaded test cases will
be made available at no cost to NIH/FDA researchers for evaluation and testing.Project Narrative:
The novel respiratory inhalation framework proposed in this project will provide an efficient, accurate and
validated computational platform to virtually test, design, and develop inhaled drug products by investigating
interactions between pulmonary delivery systems and the age-specific pediatric anatomical and physiological
systems at multiple scales. Applications of the proposed computational tool will reveal key aspects affecting the
fate of pediatric administered drugs as well as suggesting guidelines for age-specific dose calculations in
diseased states. The long term implications for the application of our developed computational tool for the entire
upper and lower airways coupled with other major organs will aid in the unmet need of suggesting and
standardizing pediatric inhaled drug doses and devices to deliver the most effective therapy and has the potential
to change the current approach to management.
Technology keywords
Not reported
Other awards by this recipient
Verified by the same UEI. These are other public SBIR/STTR award pages, not a merged company record.
Awards with the same topic code
Verified by an exact topic code match. This is not a text-similarity match.
Research funding history
947 SBIR/STTR records share this UEI (1987–2026). Reported award amounts total $350,893,199. Reported amounts are not federal obligations.
Phases: Phase I, Phase II, Phase II – Direct to Phase II
Agencies: Department of Defense, National Aeronautics and Space Administration, Department of Health and Human Services, National Science Foundation, Department of Commerce, Department of Energy
Agency intelligence
Department of Health and Human Services
Back to SBIR/STTR Research Awards